FDA's CBD Puzzle: 'Criminals' Continue Or Prohibition Ends And Research Grows

Agency seeks comment, at May 31 public hearing and docket open through July 2, on health and safety risks, manufacturing and product quality and marketing/labeling/sales around allowing cannabis-derived ingredients non-drug products. It wants input from across sectors of stakeholders, including opponents as well as proponents of allowing cannabis-derived ingredients in any category of regulated products other than drugs.

US map-cannibis-plants

Allowing cannabis-derived ingredients' use in any non-drug product available in the US allows "criminals" in "the marijuana industry" to profit, the Food and Drug Administration heard from speakers at a 31 May public hearing.

On the other hand, speakers during the agency's first-ever hearing on the use of cannabis-derived ingredients in products subject to...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation